In 2022, Domain Therapeutics and Institut Bergonié entered into a collaboration through the hospital-university research in health (RHU) CONDOR project for a precision medicine and immunotherapy of sarcoma. Institut Bergonié is the coordinating partner of RHU CONDOR, led by Prof. Antoine Italiano, who leads the “Early Phase trials and Sarcoma Unit” at Institut Bergonié and has already enabled the setup of the largest portfolio of immune-oncology trials ever performed in sarcomas.

Institut Bergonié will support part of the clinical development of Domain’s proprietary program, namely DT-9081 targeting EP4 receptor. Institut Bergonié will also give access to biobank and biomarker technology platforms and expertise to support the biomarker and positioning strategy on the DT-9081 as well as other research programs.